Welcome to our dedicated page for Sernova Biotherapeutics news (Ticker: SEOVF), a resource for investors and traders seeking the latest updates and insights on Sernova Biotherapeutics stock.
Sernova Biotherapeutics (OTCQB: SEOVF) generates frequent news as a clinical-stage regenerative medicine company advancing its Cell Pouch Bio-hybrid Organ platform for type 1 diabetes (T1D) and other chronic diseases. Its announcements focus on clinical progress, scientific collaborations, financing activities, and corporate developments that shape the trajectory of its T1D and thyroid disorder programs.
News releases from Sernova highlight interim data from its ongoing Phase 1/2 clinical trial in T1D, including reports of islet engraftment in the Cell Pouch, insulin production indicated by C-peptide, achievement of insulin independence in some patients, and improvements in HbA1c and patient-reported quality-of-life measures. These updates are central for readers tracking how the Cell Pouch Bio-hybrid Organ performs in people living with T1D, particularly those with hypoglycemia unawareness and severe hypoglycemic episodes.
Investors and observers can also follow collaborations and partnerships, such as Sernova’s agreements with Evotec for stem cell-derived islet-like clusters and with Eledon Pharmaceuticals to evaluate the immunosuppressive agent tegoprubart in a future cohort of its T1D trial. In addition, Sernova regularly reports on financing transactions, including loans, convertible debentures, and debt-to-equity conversions, which the company states are used to support working capital and clinical development plans.
Corporate governance and leadership changes, conference presentations, and updates from the company’s Data and Safety Management Board (DSMB) also appear in Sernova’s news flow. This page aggregates these items so readers can review clinical milestones, partnership developments, and capital structure updates related to Sernova Biotherapeutics and its SEOVF listing in one place.
Sernova (OTC: SEOVF) announced financing transactions totaling $7.1 million on March 4, 2026, including three private financings: $1.6M non‑brokered equity, $1.5M convertible debenture, and $4.0M insider equity subject to shareholder approval.
Proceeds will retire a $4.0M secured term loan if approved and collectively materially improve the company's capital structure and liquidity ahead of an AGM on April 8, 2026.
Sernova (OTC: SEOVF) announced proposed amendments to outstanding warrants, subject to TSX approval, effective March 6, 2026.
The company will extend 19,977,050 non‑insider warrants (originally expiring March 3, 2026) to March 3, 2027, and will amend terms of 5,571,250 October–November 2025 warrants and finders warrants by reducing the exercise price to $0.25 and adding an acceleration clause tied to a 5‑day VWAP > $0.50. Insiders' warrants will not be amended.
Sernova Biotherapeutics (OTCQB: SEOVF), a regenerative medicine company developing Cell Pouch Bio-hybrid Organ for type 1 diabetes, has announced a significant CAD $13.3 million debt-to-equity conversion of outstanding accounts payable.
The conversion was executed through a non-brokered private placement of 66.3 million units at $0.19 per unit. Each unit includes one share (common or preferred) and two half warrants exercisable at $0.25 and $0.30 for 2 and 3 years, respectively. Additionally, the company successfully negotiated to defer its $4 million term debt repayment until April 2026.
The company's management, including CEO and CFO, participated in the conversion, demonstrating internal confidence in Sernova's direction toward advancing its phase 1/2 clinical trial for type 1 diabetes treatment.
Sernova Biotherapeutics (OTCQB:SEOVF) has announced a significant collaboration with Eledon Pharmaceuticals to advance their Type 1 Diabetes (T1D) treatment program. The partnership will evaluate Eledon's immunosuppressive agent tegoprubart in Cohort C of Sernova's Phase 1/2 clinical trial of its Cell Pouch Bio-hybrid Organ.
The collaboration aims to replace tacrolimus with tegoprubart, as previous studies showed promising results where T1D patients achieved normal blood sugar levels and insulin independence. Notably, islet engraftment was 3-5 times higher with tegoprubart compared to tacrolimus-based immunosuppression, with better graft survival and function.
The partnership combines Sernova's retrievable Bio-hybrid Organ technology with Evotec's stem cell-derived islet-like clusters and Eledon's innovative immunosuppression approach, positioning it as a potential leading solution for a functional T1D cure.
Sernova Biotherapeutics (SEOVF), a regenerative medicine company developing Cell Pouch Bio-hybrid Organ for type 1 diabetes treatment, announced the resignation of its Board Chair, Ross Haghighat. The resignation was tendered on May 24th, 2025, and accepted by Sernova's Board of Directors. The company expressed gratitude for Haghighat's leadership and extended well wishes for his future endeavors.
Sernova Biotherapeutics (SEOVF) has secured a CAD$4 million secured term loan from Navigate Private Yield Fund LP III, maturing on April 16, 2026. The company, which focuses on developing Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes (T1D), will use the proceeds for working capital and general corporate purposes.
The loan, supported by a secured guarantee from Sernova's U.S. subsidiary and board member Dr. Steven Sangha, comes after raising over CAD$10 million in recent months. The company is preparing to initiate its final human donor islet Cohort C clinical trial of their Cell Pouch Bio-hybrid Organ in T1D patients, positioning itself as the most advanced company in U.S. clinical trials with an implantable and retrievable product targeting type 1 diabetes cure.
Sernova Biotherapeutics (TSX: SVA) (OTCQB: SEOVF) announced that its Cell Pouch Bio-hybrid Organ, in development as a functional cure for type 1 diabetes (T1D), will be featured at the 2025 Cell & Gene Meeting on the Med conference in Rome.
The presentation will be part of a panel discussion titled 'Diabetes – Cell and Tissue Therapy Approaches to Provide Durable Therapeutic Solutions' on April 16, 2025. Dr. Bernd Muehlenweg, Senior Vice President at Evotec and Non-Executive Director at Sernova, will present data from the Sernova-Evotec collaboration during the session.
Sernova Biotherapeutics (SEOVF) has received DSMB approval to advance its Phase 1/2 clinical trial for type 1 diabetes treatment using the Cell Pouch™ Bio-hybrid Organ system. The trial's Data and Safety Management Board has authorized enrollment of the final patient in Cohort B, with plans to progress to Cohort C in H2 2025.
The primary endpoint focuses on demonstrating safety and tolerability of islet transplantation into Cell Pouch for T1D patients with hypoglycemia unawareness. The company reports being on track to achieve this endpoint based on current clinical data.
The Cell Pouch™ system, described as the only implantable and retrievable cell containment system for islet engraftment in U.S. clinical trials, has shown islet cell survival in patients ranging from one to five years, with demonstrated ability to support insulin independence. Following trial completion, Sernova plans to initiate a new clinical trial using iPSC islet-like clusters in collaboration with Evotec.